Loading clinical trials...
Loading clinical trials...
Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older
Conditions
Interventions
mRNA NA vaccine
High Dose Quadrivalent Influenza Vaccine
Locations
6
United States
AES - DRS - Optimal Research_Site 8400007
Huntsville, Alabama, United States
Central Phoenix Medical Clinic, LLC_Site: 8400010
Phoenix, Arizona, United States
Optimal Research San Diego, LLC_Site: 8400009
San Diego, California, United States
AES - DRS - Optimal Research_Site 8400002
Melbourne, Florida, United States
AES - DRS - Optimal Research_Site 8400001
Peoria, Illinois, United States
Synexus Clinical Research_Site 8400003
Cincinnati, Ohio, United States
Start Date
June 9, 2022
Primary Completion Date
January 3, 2024
Completion Date
January 3, 2024
Last Updated
September 15, 2025
NCT07310264
NCT06342713
NCT07472361
NCT06649110
NCT06823947
NCT07240675
Lead Sponsor
Sanofi Pasteur, a Sanofi Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions